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Perfil do uso de drogas modificadoras de doença no registro brasileiro de 
espondiloartrites
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r e s u m o
Introdução: Poucos estudos avaliaram o perfil do uso de drogas modificadoras de doença 
(DMD) em pacientes brasileiros com diagnóstico de espondiloartrite (EpA). 
Métodos: Um protocolo comum de investigação foi prospectivamente aplicado em 1505 
pacientes classificados como EpA pelos critérios do Grupo Europeu de Estudo das Es-
pondiloartrites (ESSG), acompanhados em 29 centros de referência em Reumatologia no 
Brasil. Variáveis clínicas e demográficas foram obtidas e avaliadas, analisando-se suas 
correlações com o uso das DMD metotrexato (MTX) e sulfasalazina (SSZ). 
Resultados: Pelo menos uma DMD foi utilizada por 73,6% dos pacientes, sendo MTX por 
29,2% e SSZ por 21,7%, enquanto 22,7% utilizaram ambas as drogas. O uso do MTX foi sig-
nificativamente associado ao acometimento periférico, e a SSZ foi associada ao compro-
metimento axial, sendo que as duas drogas foram mais utilizadas, isoladas ou combina-
das, no comprometimento misto (p < 0,001). O uso de uma DMD esteve significativamente 
associado à etnia branca (MTX; p = 0,014), lombalgia inflamatória (SSZ; p = 0,002), dor em 
nádegas (SSZ; p = 0,030), cervicalgia (MTX; p = 0,042), artrite de membros inferiores (MTX; 
p < 0,001), artrite de membros superiores (MTX; p < 0,001), entesite (p = 0,007), dactilite 
(MTX; p < 0,001), doença inflamatória intestinal (SSZ; p < 0,001) e acometimento ungueal 
(MTX; p < 0,001). 
Conclusão: O uso de pelo menos uma DMD foi referido por mais de 70% dos pacientes 
numa grande coorte brasileira de pacientes com EpA, sendo o uso do MTX mais associado 
ao acometimento periférico e o uso da SSZ mais associado ao acometimento axial.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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Introduction: Few studies have evaluated the profile of use of disease modifying drugs (DMD) 
in Brazilian patients with spondyloarthritis (SpA).
Methods: A common research protocol was applied prospectively in 1505 patients classified 
as SpA by criteria of the European Spondyloarthropathies Study Group (ESSG), followed 
at 29 referral centers in Rheumatology in Brazil. Demographic and clinical variables were 
obtained and evaluated, by analyzing their correlation with the use of DMDs methotrexate 
(MTX) and sulfasalazine (SSZ).
Results: At least one DMD was used by 73.6 % of patients: MTX by 29.2 % and SSZ by 21.7%, 
while 22.7 % used both drugs. The use of MTX was significantly associated with peripheral 
involvement, and SSZ was associated with axial involvement, and the two drugs were more 
administered, separately or in combination, in the mixed involvement (p < 0.001). The use 
of a DMD was significantly associated with Caucasian ethnicity (MTX , p = 0.014), inflam-
matory back pain (SSZ, p = 0.002) , buttock pain (SSZ, p = 0.030), neck pain (MTX, p = 0.042), 
arthritis of the lower limbs (MTX, p < 0.001), arthritis of the upper limbs (MTX, p < 0.001), 
enthesitis (p = 0.007), dactylitis (MTX, p < 0.001), inflammatory bowel disease (SSZ, p < 0.001) 
and nail involvement (MTX, p < 0.001). 
Conclusion: The use of at least one DMD was reported by more than 70% of patients in a 
large cohort of Brazilian patients with SpA, with MTX use more associated with peripheral 
involvement and the use of SSZ more associated with axial involvement.
© 2014 Elsevier Editora Ltda. All rights reserved.
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Table 1 – Results of using DMD, according to the clinical 
picture.
MTX(%) SSZ 
(%)
MTX + SSZ (%) p
Mixed 51.8 46.2 58.1
Axial 24.4 43.0 24.3 < 0.001
Peripheral 19.2 4.9 8.3
Enthesial 4.6  5.9 9.3
DMD, disease modifying drug, MTX, methotrexate, SSZ, 
sulfasalazine.
Introduction
Spondyloarthritides are a group of chronic inflammatory dis-
eases with similar clinical and genetic characteristics, which 
allows their analysis within the same group. Ankylosing 
spondylitis (AS) is a disease with predominantly axial clini-
cal impairment, while psoriatic arthritis (PA), reactive arthri-
tis, arthritis associated with inflammatory bowel disease and 
undifferentiated SpA often show an important peripheral in-
volvement.1 Recognizing this extension of the concept itself, 
SpAs were recently classified into axial2 and peripheral3. The 
evaluation of Brazilian4 and Latin American5 patients with 
SpA reveals that, besides the characteristic axial involve-
ment, often a significant number of patients with peripheral 
involvement are detected.
Studies evaluating the treatment of SpA, especially AS6,7 
and PA,8,9 show that the use of disease-modifying drugs 
(DMD), such as methotrexate, sulfasalazine, and leflunomide, 
is related more to the involvement of the peripheral versus 
axial involvement.
This study analyzes the prescription of DMD for a large 
cohort of Brazilian patients with SpA.
Patients and methods
This is a prospective, observational, multicenter study with 
1505 patients from 29 referral centers participating in the Reg-
istro Brasileiro de Espondiloartrites (RBE). All patients fulfilled 
the criteria of the European Group for the Study of Spondylo-
arthropathies (ESSG).10 Data were collected from June 2006 to 
December 2009. The BRS participates in RESPONDIA (Regis-
tro Iberoamericano de Espondiloartrites) group, consisting of 
nine Latin American countries (Argentina, Brazil, Costa Rica, 
Chile, Ecuador, Mexico, Peru, Uruguay and Venezuela) and the 
two countries of the Iberian Peninsula (Spain and Portugal) .
The joint investigation protocol included demographic 
(gender, race, family history, HLA-B27), osteoarticular clinical 
(inflammatory back pain, buttock pain, neck pain, hip pain, 
lower extremity arthritis, arthritis of the lower limbs, en-
thesitis, dactylitis), extra-articular clinical (uveitis, inflamma-
tory bowel disease [IBD], psoriasis, urethritis), and laboratory 
(erythrocyte sedimentation rate - ESR and C-reactive protein 
- CRP) variables.
Patients were evaluated for treatment with nonsteroidal 
anti-inflammatory drugs (NSAIDs), corticosteroids, DMD 
and biological agents. Regarding the use of DMD, metho-
trexate (MTX), sulfasalazine (SSZ) and leflunomide (LFN) 
were evaluated.
For the diagnosis of AS, New York criteria were used;11 
for psoriatic arthritis, the patients had to meet the criteria 
of Moll and Wright.12 The diagnosis of reactive arthritis was 
considered if were present: asymmetric oligoarthritis of the 
lower limbs with enthesopathies and/or inflammatory lum-
bar pain arousing after enteric or urogenital infection,13 and 
spondylitis/arthritis associated with inflammatory bowel dis-
ease, if the patient showed inflammatory axial features and/
or peripheral joint involvement, associated with confirmed 
Crohn's disease or ulcerative colitis.
Statistical analysis. Categorical variables were compared us-
ing χ2 and Fisher exact test, and continuous variables were 
compared using ANOVA. A value of p <0.05 was considered 
significant, and 0.05> p> 0.10 was considered as statistical 
trend.
Results
Data analysis revealed that at least one DMD was used by 
73.6% of patients; 51.9% reported the use of MTX - 29.2% as 
monotherapy and 22.7% with SSZ; and 44.4% used SSZ, of 
whom 21.7% as monotherapy. The use of leflunomide was re-
ported by 0.2% of patients; for this reason, this agent was not 
included in the statistical analysis.
With respect to joint involvement, MTX was significantly 
associated with peripheral involvement and SSZ was asso-
ciated with axial involvement, and the two drugs were used 
more often, as monotherapy or in combination, in the mixed 
involvement (p < 0.001) (Table 1).
The demographic variables showed that MTX was associ-
ated with Caucasian ethnicity (p = 0.014). Gender, family his-
tory and HLA-B27 were not associated with the use of any 
DMD (Table 2).
With respect to the clinical picture, MTX was significantly 
associated with cervical involvement (p = 0.042), arthritis of 
the lower limbs (p < 0.001), arthritis of the upper limbs (p < 
0.001), cutaneous psoriasis (p < 0.001), dactylitis (p < 0.001) 
and nail involvement (p < 0.001). By the other hand, SSZ was 
associated with inflammatory back pain (p = 0.002), buttock 
pain (p = 0.030) and inflammatory bowel disease (p < 0.001), 
while the use of both drugs was associated with enthesites 
(p = 0.007). Coxofemoral pain, anterior uveitis and urethritis 
showed no association with the use of DMD (Table 3).
Discussion
This study confirms that the use of DMD is very common in 
Brazilian patients. In this multicenter study, which included 
patients from the five Brazilian regions (Southeast, South, 
Midwest, Northeast and North), the use of at least one DMD 
was reported by nearly three in four patients with SpA, with 
51.7% to MTX and 44.4% to SSZ. The use of at least one DMD 
may be greatly associated with the significant number of pa-
tients with peripheral joint and mixed involvement observed 
in our cases.4 A study evaluating 216 patients with AS in Tur-
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key revealed that 77.5% received SSZ and 15% MTX, and 9% 
received anti-TNF agents.14
The use of MTX has been studied in AS in the past two 
decades. Considering in general that its use is indicated for 
patients with predominantly axial involvement, the clinical 
response was not favorable;15-17 the only two studies that dem-
onstrated a better response to MTX were Latin American: one 
Brazilian18 and one Mexican.19 Also, the use of MTX for short 
period of time (16 weeks) might not be enough for the desired 
effect of the medication. On the other hand, MTX has been 
used for over 50 years in PA patients, with good results,21-23 
being the basal drug of first choice.
The present study confirmed this trend of MTX use in cases 
of peripheral involvement, associated or not with axial involve-
ment. Statistical association with arthritis of the lower and up-
per limbs was noted. The association with Caucasians seems 
to be related to the presence of psoriasis and its sequels (dacty-
litis and nail involvement) as shown in the literature. 24,25
Sulfasalazine is the most commonly used conventional 
DMD in AS.6 Its use in AS comes from the 1980s, and its main 
action would be in cases of associated peripheral involve-
ment.26,27 The same action profile is observed in PA.28-30 SSZ is 
also used in the case of reactive arthritis with gastrointestinal 
etiology31 and in the arthritides associated with inflammatory 
bowel disease.32.33 In contrast to what is traditionally observed 
in the literature, the use of SSZ in the present study was asso-
ciated with axial involvement, particularly inflammatory low 
back pain and buttock pain, and with enteropathic arthritis.
However, although SSZ is significantly more used than 
MTX in patients with inflammatory bowel disease, it is note-
worthy that less than 9% of patients with this type of impair-
ment were using SSZ. The explanation for this use in patients 
with axial involvement lies in the fact that many rheumatol-
ogy services in Brazil use empirically at least one DMD, pref-
erably SSZ, in patients with AS, before prescribing biological 
agents, since we have an impressive number of patients with 
mixed (axial and peripheral) joint involvement. Regarding the 
entheseal involvement, quite frequent in our series,34 is com-
mon practice the prescription of both MTX and SSZ, as mono-
therapy or in combination, for its treatment.
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Erratum
There is an error on the year on the headings of issue 1 of 
volume 54 of Brazilian Journal of Rheumatology: in all pag-
es, where it reads: REV BRAS REUMATOL 2013;54(1): and the 
number of the pages, it should read: REV BRAS REUMATOL 
2014;54(1): and the number of the pages
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